 SOUTH SAN FRANCISCO and SAN DIEGO, Sept. 21, 2021 GLOBE NEWSWIRE -- ORIC Pharmaceuticals, Inc. Nasdaq: ORIC, a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced an update on its CD73 inhibitor program. ORIC recently announced the U.S. Food and Drug Administration FDA has cleared the companys Investigational New Drug Application IND for ORIC-533 to proceed into a first-in-human clinical trial in which ORIC-533 will be tested as a single agent in an undisclosed tumor type not currently known to be under clinical evaluation with any other CD73 inhibitor. ORIC-533 was discovered internally at ORIC, is wholly owned, and is a highly potent, orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy and immunotherapy-based treatment regimens. 